How conspiracy theories about Covid's origins are hampering our ability to prevent the next pandemic
The report concluded that although we don't know conclusively where the virus that caused the pandemic came from: a zoonotic origin with spillover from animals to humans is currently considered the best supported hypothesis. Sago did not find scientific evidence to support 'a deliberate manipulation of the virus in a laboratory and subsequent biosafety breach'.
This follows a series of reports and research papers since the early days of the pandemic that have reached similar conclusions: Covid most likely emerged from an infected animal at the Huanan market in Wuhan, and was not the result of a lab leak.
But conspiracy theories about Covid's origins persist. And this is hampering our ability to prevent the next pandemic.
Attacks on our research
As experts in the emergence of viruses, we published a peer-reviewed paper in Nature Medicine in 2020 on the origins of Sars-CoV-2, the virus that causes Covid.
Like Sago, we evaluated several hypotheses for how a novel coronavirus could have emerged in Wuhan in late 2019. We concluded the virus very likely emerged through a natural spillover from animals – a 'zoonosis' – caused by unregulated wildlife trade in China.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
Since then, our paper has become a focal point of conspiracy theories and political attacks.
The idea Sars-CoV-2 might have originated in a laboratory is not, in itself, a conspiracy theory. Like many scientists, we considered that possibility seriously. And we still do, although evidence hasn't emerged to support it.
But the public discourse around the origin of the pandemic has increasingly been shaped by political agendas and conspiratorial narratives. Some of this has targeted our work and vilified experts who have studied this question in a data-driven manner.
A common conspiracy theory claims senior officials pressured us to promote the 'preferred' hypothesis of a natural origin, while silencing the possibility of a lab leak. Some conspiracy theories even propose we were rewarded with grant funding in exchange.
These narratives are false. They ignore, dismiss or misrepresent the extensive body of evidence on the origin of the pandemic. Instead, they rely on selective quoting from private discussions and a distorted portrayal of the scientific process and the motivations of scientists.
So what does the evidence tell us?
In the five years since our Nature Medicine paper, a substantial body of new evidence has emerged that has deepened our understanding of how Sars-CoV-2 most likely emerged through a natural spillover.
In early 2020, the case for a zoonotic origin was already compelling. Much-discussed features of the virus are found in related coronaviruses and carry signatures of natural evolution. The genome of Sars-CoV-2 showed no signs of laboratory manipulation.
The multi-billion-dollar wildlife trade and fur farming industry in China regularly moves high-risk animals, frequently infected with viruses, into dense urban centres. It's believed that Sars-CoV-1, the virus responsible for the Sars outbreak, emerged this way in 2002 in China's Guangdong province.
Similarly, detailed analyses of epidemiological data show the earliest known Covid cases clustered around the Huanan live-animal market in Wuhan, in the Hubei province, in December 2019.
Multiple independent data sources – including early hospitalisations, excess pneumonia deaths, antibody studies and infections among healthcare workers – indicate Covid first spread in the district where the market is located.
In a 2022 study, we and other experts showed that environmental samples positive for Sars-CoV-2 clustered in the section of the market where wildlife was sold.
In a 2024 follow-up study, we demonstrated those same samples contained genetic material from susceptible animals – including raccoon dogs and civets – on cages, carts, and other surfaces used to hold and transport them.
This doesn't prove infected animals were the source. But it's precisely what we would expect if the market was where the virus first spilled over. And it's contrary to what would be expected from a lab leak.
These and all other independent lines of evidence point to the Huanan market as the early epicentre of the Covid pandemic.
Hindering preparedness for the next pandemic
Speculation and conspiracy theories around the origin of Covid have undermined trust in science. The false balance between lab leak and zoonotic origin theories assigned by some commentators has added fuel to the conspiracy fire.
This anti-science agenda, stemming in part from Covid origin conspiracy theories, is being used to help justify deep cuts to funding for biomedical research, public health and global aid. These areas are essential for pandemic preparedness.
In the US this has meant major cuts to the US Centers for Disease Control and the National Institutes of Health, the closure of the US Agency for International Development, and withdrawal from WHO.
Undermining trust in science and public health institutions also hinders the development and uptake of life-saving vaccines and other medical interventions. This leaves us more vulnerable to future pandemics.
The amplification of conspiracy theories about the origin of Covid has promoted a dangerously flawed understanding of pandemic risk. The idea that a researcher discovered or engineered a pandemic virus, accidentally infected themselves, and unknowingly sparked a global outbreak (in exactly the type of setting where natural spillovers are known to occur) defies logic. It also detracts from the significant risk posed by the wildlife trade.
In contrast, the evidence-based conclusion that the Covid pandemic most likely began with a virus jumping from animals to humans highlights the very real risk we increasingly face. This is how pandemics start, and it will happen again. But we're dismantling our ability to stop it or prepare for it. THE CONVERSATION
Edward Holmes is an NHMRC leadership fellow and professor of virology at University of Sydney. Andrew Rambaut is professor of molecular evolution at University of Edinburgh. Kristian Andersen is professor and director of infectious disease genomics at The Scripps Research Institute. Robert Garry is professor of microbiology and immunology at Tulane University.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Straits Times
a day ago
- Straits Times
Pfizer and BioNTech lose UK court appeal over Covid-19 jab
Sign up now: Get ST's newsletters delivered to your inbox Moderna has accused Pfizer and BioNTech of violating its intellectual property rights with regard to mRNA technology. LONDON - US pharmaceutical giant Pfizer and German firm BioNTech lost on Aug 1 a court appeal in the latest step of a multi-million pound battle against US rival Moderna over the Covid-19 vaccine. The Appeals Court in London upheld an earlier UK court decision in the long-running battle between the global pharma firms. It found that one of the European patents held by Moderna was invalid, but that a second one had been broken by Pfizer and its German partner BioNTech. 'The judge made no error of law or principle' in the ruling handed down in July 2024, the Appeal Court judges wrote Friday, dismissing the appeal brought by the two companies. Pfizer quickly said it will appeal the Aug 1 ruling to Britain's Supreme Court. 'Today's UK Court of Appeal's decision does not change our unwavering stance that this patent is invalid,' Pfizer said in a statement. 'This decision has no immediate impact on Pfizer and BioNTech.' Pfizer and BioNTech had argued that both the patents cited by Moderna were invalid, and neither had been infringed. The Aug 1 decision could have wide implications for other cases involving the huge pharma companies in the United States, Germany, Belgium, the Netherlands and Ireland. Moderna said in a statement it was pleased with the Aug 1 ruling and would 'continue to pursue and enforce its patent rights globally to protect its innovative mRNA technology'. A UK court was told in 2024 the firms had spent £19 million (S$32 million) fighting their legal battles. In 2020, Pfizer and BioNTech's vaccine became the first ever mRNA vaccine approved for widespread use, and was swiftly deployed to combat the Covid-19 pandemic. Scientists believe mRNA vaccines, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against many diseases. Traditional vaccines contain some form of the dead or inactivated target virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than traditional vaccines. In March, a German court in Duesseldorf also found Pfizer and BioNTech had violated a Moderna patent filed between 2010 to 2016 to make their vaccines. It ordered they must provide estimates of how much they had profited from breaking the patent as well as provide 'appropriate compensation'. AFP
Business Times
2 days ago
- Business Times
Moderna to cut 10% of staff to offset slowing Covid business
[CAMBRIDGE, MASSACHUSETTS] Moderna is cutting about 10 per cent of its workforce, part of an effort by the struggling biotech company to reduce spending as sales of its Covid vaccine decline. In a note to employees, chief executive officer Stéphane Bancel said the company was 'aligning our cost structure to the realities of our business.' The layoffs will affect hundreds of employees globally, though Bancel did not disclose in which areas of the business. Moderna expects to have fewer than 5,000 employees by the end of the year, he said. It had about 5,800 full-time employees at the end of last year, according to a company filing. Moderna is cutting costs as revenue from its Covid vaccine shrinks and the company faces new challenges from the leadership of Health and Human Services Secretary Robert F Kennedy Jr, a vaccine critic. Under Kennedy, US health officials have rolled back long-standing recommendations regarding Covid shots for children and pregnant women, approved Moderna's updated Covid shot for a narrower group of people and terminated the company's contract to develop bird flu vaccines. Meanwhile Moderna's second product, a vaccine for RSV, has not gained traction. With sales falling short of investors' expectations, Moderna last year pushed back its target to break even by two years, to 2028 from 2026. The company has said it plans to reduce annual operating expenses by about US$1.5 billion by 2027. Moderna is doing that by renegotiating supplier agreements, reducing manufacturing costs and lowering spending on research and development. BLOOMBERG

Straits Times
3 days ago
- Straits Times
SingHealth nurses get $5.7m from Wee Foundation for education, skills development
Sign up now: Get ST's newsletters delivered to your inbox Ms Wee Wei Ling, Wee Foundation director (right), and Senior Minister of State for Health Tan Kiat How serve nurses during the SingHealth Nurses' Day celebrations. SINGAPORE – SingHealth nurses will be receiving a further $5.7 million from the Wee Foundation to advance their education and provide them with more training opportunities . This comes after the charitable organisation gave the healthcare cluster nurses $5 million for educational and professional development in 2022, when it established a nursing academic fund for that purpose. Wee Foundation director Wee Wei Ling told The Straits Times on July 29: 'Nurses are the backbone of healthcare, providing selfless dedication. They go out of their way, especially during the Covid-19 pandemic, working day and night caring for the sick. 'The Wee Foundation felt they deserve our help in providing them scholarships to further their studies and funding for innovations.' Linked to the late Dr Wee Cho Yaw, a banker and philanthropist, the Wee Foundation was set up in February 2009 with an initial S$30 million endowment from the Wee family. The charitable foundation focuses on education and welfare for the underprivileged, and also promotes Chinese language and culture, as well as social integration. In 2022, the Wee Foundation Nursing Academic Fund was established with an inaugural $5 million to advance nurses' capabilities through higher education and postgraduate studies. It also offered them training grants to become competent in areas such as digitalisation, artificial intelligence (AI), robotics and global health. Top stories Swipe. Select. Stay informed. Singapore SMRT's finances hit by 2024 EWL disruption; profit after tax for trains division dips 8% Asia US-Malaysia tariff deal set for Aug 1 after Trump-Anwar phone call Business Deepening S'pore-Latin America ties a matter of urgency amid global trade uncertainty: Alvin Tan Singapore Underground pipe leak likely reason for water supply issues during Toa Payoh fire: Town council Multimedia 60 years, 60 items: A National Day game challenge Life Milo tees, kaya toast pimple patches, crockery: Here are the SG60 merch to collect Singapore 'Switching careers just as I became a dad was risky, but I had to do it for my family' Since then, the fund has helped 970 SingHealth nurses through different educational opportunities. One of them is Ms Reina Cheong, 26, a staff nurse with the Singapore General Hospital (SGH). Ms Cheong, who used to spend long hours draining fluid from the abdomen of patients with abdominal swelling, felt there was a safer and more efficient way of doing this. Ms Reina Cheong, a staff nurse at Singapore General Hospital, will be developing a mechanical pump to make it safer and more efficient to drain excess fluid from the abdomen of cancer patients. ST PHOTO: BRIAN TEO 'Draining this fluid manually is time-consuming and needs the constant attention of the nurse, especially when large amounts of fluid are involved,' she said. Ms Cheong explained that the rate at which fluid is removed is crucial because 'too much and too fast can result in a drop in blood pressure and, in severe cases, hypovolaemic shock', a life-threatening condition when the body loses too much blood or fluid. She came up with the idea of a mechanical device that automatically stops when the drainage reaches the safe limit and pitched this solution at the 2024 SingHealth Nursing Innovation Challenge. Her team was later given seed fundin g for a feasible pilot project. Currently, Ms Cheong is working with a company to develop her pump. A total of 116 nurses received the Wee Foundation Nurses' Day Awards on July 29 and another 32 nurses were given the Wee Foundation Nursing Scholarships to further their studies.